X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IPL344 is a biologically active peptide that stimulates therapeutic cell-signaling processes including activation of the Akt pathway. It is under phase 2 clinical development for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): IPL344
Therapeutic Area: Neurology Product Name: IPL344
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
In this early stage clinical trial, disease progression rate during IPL344 treatment was about 50% slower than expected without treatment, in both functional and respiratory endpoints. The drug also demonstrated a very favorable safety and tolerability profile.
Lead Product(s): IPL344
Therapeutic Area: Neurology Product Name: IPL344
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
